{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:20:05Z","timestamp":1790400005198,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Off-target binding remains a significant challenge in tau-PET neuroimaging. While off-targets including monoamine oxidase enzymes and neuromelanin-containing cells have been identified, recent studies indicated a relevant binding of novel tau tracers to melanin-containing structures. To date, little is known about the effect of melanocytes in the meninges on tracer signals in brain PET data. Thus, we aimed to identify the target structure causal for the frequently observed [<jats:sup>18<\/jats:sup>F]PI-2620 PET signal in the vermis and adjacent cerebellar regions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>274 participants underwent dynamic [<jats:sup>18<\/jats:sup>F]PI-2620 tau-PET: 3\/4R-tauopathies (n\u2009=\u200985), 4R-tauopathies (n\u2009=\u2009147), tau-negative disease controls (n\u2009=\u200924), and healthy controls (n\u2009=\u200918). Standardized uptake value ratio (SUVR) and kinetic parameters including the distribution volume ratio (DVR), tracer clearance (k2) and relative perfusion (R1), were compared among the cohorts and sexes using the Automated Anatomical Labelling (AAL) atlas. Age and p-Tau levels in cerebrospinal fluid (CSF) were assessed for their relationship with vermal tau-PET signal. Furthermore, we combined autoradiographic and histochemical experiments on post-mortem brain tissue of deceased patients (n\u2009=\u20099).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Male participants revealed higher mean vermal [<jats:sup>18<\/jats:sup>F]PI-2620 DVR (0.95\u2009\u00b1\u20090.13; vs. females 0.88\u2009\u00b1\u20090.10, p\u2009&lt;\u20090.0001). Sex-related differences were most pronounced in the 3\/4R-tauopathy cohort (p\u2009&lt;\u20090.0001). Mean SUVR<jats:sub>Ver\/Cbl<\/jats:sub>, k2 and correlation analyses of kinetic parameters did not differ among groups. Histological assessments revealed co-localization of leptomeningeal pigmented cells with strong autoradiography signal spots within the vermal fissures. Tau-related autoradiography signals, age or p-Tau levels did not correlate significantly with tau-PET signals. Iron deposits did not cause relevant autoradiography signals in the vermis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Leptomeningeal melanocytes are the primary target structure for [<jats:sup>18<\/jats:sup>F]PI-2620 PET binding in anterior vermis, whereas iron and tau deposits do not contribute significantly.\n<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00259-025-07199-x","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T06:15:28Z","timestamp":1742278528000},"page":"3519-3533","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Exploring the origins of frequent tau-PET signal in vermal and adjacent regions"],"prefix":"10.1007","volume":"52","author":[{"given":"Agnes","family":"Kling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Kusche-Palenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Palleis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"J\u00e4ck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Bernhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Frontzkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian N.","family":"Roemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luna","family":"Slemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirlind","family":"Zaganjori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Scheifele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Paeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard N.","family":"Bischof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thilo","family":"van Eimeren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Drzezga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Sabri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rullmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henryk","family":"Barthel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Herms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolai","family":"Franzmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter","family":"H\u00f6glinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrun","family":"Roeber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Brendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1554-7765","authenticated-orcid":false,"given":"Johannes","family":"Gn\u00f6rich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"issue":"2","key":"7199_CR1","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/j.1460-2075.1989.tb03390.x","volume":"8","author":"M Goedert","year":"1989","unstructured":"Goedert M, et al. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. Embo j. 1989;8(2):393\u20139.","journal-title":"Embo j"},{"issue":"5","key":"7199_CR2","doi-asserted-by":"publisher","first-page":"3606","DOI":"10.1002\/alz.13784","volume":"20","author":"S Buchholz","year":"2024","unstructured":"Buchholz S, Zempel H. The six brain-specific TAU isoforms and their role in Alzheimer\u2019s disease and related neurodegenerative dementia syndromes. Alzheimers Dement. 2024;20(5):3606\u201328.","journal-title":"Alzheimers Dement"},{"issue":"8","key":"7199_CR3","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/s41380-018-0342-8","volume":"24","author":"A Leuzy","year":"2019","unstructured":"Leuzy A, et al. Tau PET imaging in neurodegenerative tauopathies-still a challenge. Mol Psychiatry. 2019;24(8):1112\u201334.","journal-title":"Mol Psychiatry"},{"issue":"11","key":"7199_CR4","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1001\/jamaneurol.2020.2526","volume":"77","author":"M Brendel","year":"2020","unstructured":"Brendel M, et al. Assessment of 18F-PI-2620 as a biomarker in progressive supranuclear palsy. JAMA Neurol. 2020;77(11):1408\u201319.","journal-title":"JAMA Neurol"},{"issue":"1","key":"7199_CR5","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1038\/s41467-022-28896-3","volume":"13","author":"N Franzmeier","year":"2022","unstructured":"Franzmeier N, et al. Tau deposition patterns are associated with functional connectivity in primary tauopathies. Nat Commun. 2022;13(1):1362.","journal-title":"Nat Commun"},{"issue":"3","key":"7199_CR6","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1038\/s41380-022-01875-2","volume":"28","author":"ML Malarte","year":"2023","unstructured":"Malarte ML, et al. Discriminative binding of tau PET tracers PI2620, MK6240 and RO948 in Alzheimer\u2019s disease, corticobasal degeneration and progressive supranuclear palsy brains. Mol Psychiatry. 2023;28(3):1272\u201383.","journal-title":"Mol Psychiatry"},{"issue":"1","key":"7199_CR7","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neuron.2020.09.042","volume":"109","author":"K Tagai","year":"2021","unstructured":"Tagai K, et al. High-contrast in vivo imaging of tau pathologies in Alzheimer\u2019s and non-Alzheimer\u2019s disease tauopathies. Neuron. 2021;109(1):42\u201358.e8.","journal-title":"Neuron"},{"issue":"1","key":"7199_CR8","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s00401-024-02834-7","volume":"148","author":"L Slemann","year":"2024","unstructured":"Slemann L, et al. Neuronal and oligodendroglial, but not astroglial, tau translates to in vivo tau PET signals in individuals with primary tauopathies. Acta Neuropathol. 2024;148(1):70.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"7199_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00401-023-02672-z","volume":"147","author":"C Aguero","year":"2024","unstructured":"Aguero C, et al. Head-to-head comparison of [18F]-Flortaucipir, [18F]-MK-6240 and [18F]-PI-2620 postmortem binding across the spectrum of neurodegenerative diseases. Acta Neuropathol. 2024;147(1):25.","journal-title":"Acta Neuropathol"},{"issue":"11","key":"7199_CR10","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1177\/0271678X211018904","volume":"41","author":"M Song","year":"2021","unstructured":"Song M, et al. Binding characteristics of [(18)F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET. J Cereb Blood Flow Metab. 2021;41(11):2957\u201372.","journal-title":"J Cereb Blood Flow Metab"},{"key":"7199_CR11","doi-asserted-by":"publisher","unstructured":"Dilcher R, et al. Combining cerebrospinal fluid and PI-2620 tau-PET for biomarker-based stratification of Alzheimer\u2019s disease and 4R-tauopathies. Alzheimers Dement. 2024;20(10):6896\u20136909.\u00a0https:\/\/doi.org\/10.1002\/alz.14185.","DOI":"10.1002\/alz.14185"},{"key":"7199_CR12","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.dadm.2018.01.007","volume":"10","author":"L Lemoine","year":"2018","unstructured":"Lemoine L, et al. Tau positron emission tomography imaging in tauopathies: the added hurdle of off-target binding. Alzheimers Dement (Amst). 2018;10:232\u20136.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"3","key":"7199_CR13","doi-asserted-by":"publisher","first-page":"452","DOI":"10.2967\/jnumed.122.264434","volume":"64","author":"C Tissot","year":"2023","unstructured":"Tissot C, et al. The association of age-related and off-target retention with longitudinal quantification of [(18)F]MK6240 tau PET in target regions. J Nucl Med. 2023;64(3):452\u20139.","journal-title":"J Nucl Med"},{"issue":"4","key":"7199_CR14","doi-asserted-by":"publisher","first-page":"p. fcab190","DOI":"10.1093\/braincomms\/fcab190","volume":"3","author":"T Tezuka","year":"2021","unstructured":"Tezuka T, et al. Evaluation of [(18)F]PI-2620, a second-generation selective tau tracer, for assessing four-repeat tauopathies. Brain Commun. 2021;3(4):fcab190.","journal-title":"Brain Commun"},{"issue":"10","key":"7199_CR15","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1007\/s00259-019-04397-2","volume":"46","author":"H Kroth","year":"2019","unstructured":"Kroth H, et al. Discovery and preclinical characterization of [(18)F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer\u2019s disease and other tauopathies. Eur J Nucl Med Mol Imaging. 2019;46(10):2178\u201389.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"17","key":"7199_CR16","doi-asserted-by":"publisher","first-page":"12808","DOI":"10.1021\/acs.jmedchem.1c00861","volume":"64","author":"H Kroth","year":"2021","unstructured":"Kroth H, et al. PI-2620 lead optimization highlights the importance of off-target assays to develop a PET tracer for the detection of pathological aggregated tau in Alzheimer\u2019s disease and other tauopathies. J Med Chem. 2021;64(17):12808\u201330.","journal-title":"J Med Chem"},{"issue":"1","key":"7199_CR17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40478-016-0315-6","volume":"4","author":"VJ Lowe","year":"2016","unstructured":"Lowe VJ, et al. An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun. 2016;4(1):58.","journal-title":"Acta Neuropathol Commun"},{"issue":"4","key":"7199_CR18","doi-asserted-by":"publisher","first-page":"671","DOI":"10.2967\/jnumed.117.197426","volume":"59","author":"R Harada","year":"2018","unstructured":"Harada R, et al. Correlations of 18F-THK5351 PET with postmortem burden of tau and astrogliosis in Alzheimer disease. J Nucl Med. 2018;59(4):671\u20134.","journal-title":"J Nucl Med"},{"issue":"5","key":"7199_CR19","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/ana.24517","volume":"78","author":"M Marqui\u00e9","year":"2015","unstructured":"Marqui\u00e9 M, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015;78(5):787\u2013800.","journal-title":"Ann Neurol"},{"issue":"1","key":"7199_CR20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40478-019-0686-6","volume":"7","author":"C Aguero","year":"2019","unstructured":"Aguero C, et al. Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue. Acta Neuropathol Commun. 2019;7(1):37.","journal-title":"Acta Neuropathol Commun"},{"issue":"4","key":"7199_CR21","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2478\/s11535-013-0141-1","volume":"8","author":"M Cichorek","year":"2013","unstructured":"Cichorek M, Wachulska M, Stasiewicz A. Heterogeneity of neural crest-derived melanocytes. Open Life Sci. 2013;8(4):315\u201330.","journal-title":"Open Life Sci"},{"key":"7199_CR22","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.dib.2017.10.024","volume":"15","author":"SL Baker","year":"2017","unstructured":"Baker SL, Maass A, Jagust WJ. Considerations and code for partial volume correcting [(18)F]-AV-1451 tau PET data. Data Brief. 2017;15:648\u201357.","journal-title":"Data Brief"},{"issue":"12","key":"7199_CR23","doi-asserted-by":"publisher","first-page":"3302","DOI":"10.1177\/0271678X211031035","volume":"41","author":"SL Baker","year":"2021","unstructured":"Baker SL, et al. Evaluation of [(18)F]-JNJ-64326067-AAA tau PET tracer in humans. J Cereb Blood Flow Metab. 2021;41(12):3302\u201313.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"12","key":"7199_CR24","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.2967\/jnumed.118.214437","volume":"59","author":"H Kuwabara","year":"2018","unstructured":"Kuwabara H, et al. Evaluation of 18F-RO-948 PET for quantitative assessment of tau accumulation in the human brain. J Nucl Med. 2018;59(12):1877\u201384.","journal-title":"J Nucl Med"},{"issue":"1","key":"7199_CR25","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2967\/jnumed.118.209650","volume":"60","author":"TJ Betthauser","year":"2019","unstructured":"Betthauser TJ, et al. In vivo characterization and quantification of neurofibrillary tau PET radioligand (18)F-MK-6240 in humans from Alzheimer disease dementia to young controls. J Nucl Med. 2019;60(1):93\u20139.","journal-title":"J Nucl Med"},{"key":"7199_CR26","doi-asserted-by":"publisher","first-page":"102708","DOI":"10.1016\/j.nicl.2021.102708","volume":"31","author":"R Smith","year":"2021","unstructured":"Smith R, et al. Sex differences in off-target binding using tau positron emission tomography. NeuroImage: Clinical. 2021;31:102708.","journal-title":"NeuroImage: Clinical"},{"issue":"7","key":"7199_CR27","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1007\/s00259-020-04923-7","volume":"48","author":"EC Mormino","year":"2021","unstructured":"Mormino EC, et al. Tau PET imaging with 18F-PI-2620 in aging and neurodegenerative diseases. Eur J Nucl Med Mol Imaging. 2021;48(7):2233\u201344.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"7199_CR28","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"GU H\u00f6glinger","year":"2017","unstructured":"H\u00f6glinger GU, et al. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord. 2017;32(6):853\u201364.","journal-title":"Mov Disord"},{"issue":"5","key":"7199_CR29","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","volume":"80","author":"MJ Armstrong","year":"2013","unstructured":"Armstrong MJ, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80(5):496\u2013503.","journal-title":"Neurology"},{"key":"7199_CR30","doi-asserted-by":"crossref","unstructured":"Jack CR, Jr, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimers Dement. 2024;20(8):5143\u201369.","DOI":"10.1002\/alz.095054"},{"issue":"6","key":"7199_CR31","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1002\/mds.29005","volume":"37","author":"GK Wenning","year":"2022","unstructured":"Wenning GK, et al. The movement disorder society criteria for the diagnosis of multiple system atrophy. Mov Disord. 2022;37(6):1131\u201348.","journal-title":"Mov Disord"},{"issue":"1","key":"7199_CR32","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88\u2013100.","journal-title":"Neurology"},{"issue":"12","key":"7199_CR33","doi-asserted-by":"publisher","first-page":"3872","DOI":"10.1007\/s00259-021-05391-3","volume":"48","author":"M Song","year":"2021","unstructured":"Song M, et al. Feasibility of short imaging protocols for [(18)F]PI-2620 tau-PET in progressive supranuclear palsy. Eur J Nucl Med Mol Imaging. 2021;48(12):3872\u201385.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"7199_CR34","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1097\/01.WCB.0000033967.83623.34","volume":"22","author":"Y Wu","year":"2002","unstructured":"Wu Y, Carson RE. Noise reduction in the simplified reference tissue model for neuroreceptor functional imaging. J Cereb Blood Flow Metab. 2002;22(12):1440\u201352.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"7","key":"7199_CR35","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1007\/s00259-020-05183-1","volume":"48","author":"J Seemiller","year":"2021","unstructured":"Seemiller J, et al. Indication of retrograde tau spreading along Braak stages and functional connectivity pathways. Eur J Nucl Med Mol Imaging. 2021;48(7):2272\u201382.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"7199_CR36","doi-asserted-by":"publisher","first-page":"5833","DOI":"10.1002\/alz.13908","volume":"20","author":"A Leuzy","year":"2024","unstructured":"Leuzy A, et al. Harmonizing tau positron emission tomography in Alzheimer\u2019s disease: The CenTauR scale and the joint propagation model. Alzheimers Dement. 2024;20(9):5833\u201348.","journal-title":"Alzheimers Dement"},{"issue":"12","key":"7199_CR37","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1007\/s00259-020-04788-w","volume":"47","author":"L Beyer","year":"2020","unstructured":"Beyer L, et al. Early-phase [(18)F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury. Eur J Nucl Med Mol Imaging. 2020;47(12):2911\u201322.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"7199_CR38","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/brain\/aww027","volume":"139","author":"R Ossenkoppele","year":"2016","unstructured":"Ossenkoppele R, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer\u2019s disease. Brain. 2016;139(5):1551\u201367.","journal-title":"Brain"},{"key":"7199_CR39","doi-asserted-by":"publisher","unstructured":"Bischof GN, et al.\u00a0Improved Tau PET SUVR quantification in 4-repeat tau phenotypes with [18F] PI-2620. J Nucl Med. 2024;65(6):952\u201355.\u00a0https:\/\/doi.org\/10.2967\/jnumed.123.265930.","DOI":"10.2967\/jnumed.123.265930"},{"issue":"6","key":"7199_CR40","doi-asserted-by":"publisher","first-page":"eaaw6404","DOI":"10.1126\/sciadv.aaw6404","volume":"5","author":"S Wegmann","year":"2019","unstructured":"Wegmann S, et al. Experimental evidence for the age dependence of tau protein spread in the brain. Sci Adv. 2019;5(6):eaaw6404.","journal-title":"Sci Adv"},{"issue":"5","key":"7199_CR41","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.neuron.2016.01.028","volume":"89","author":"M Sch\u00f6ll","year":"2016","unstructured":"Sch\u00f6ll M, et al. PET imaging of tau deposition in the aging human brain. Neuron. 2016;89(5):971\u201382.","journal-title":"Neuron"},{"issue":"8","key":"7199_CR42","doi-asserted-by":"publisher","first-page":"e14398","DOI":"10.15252\/emmm.202114398","volume":"13","author":"R Ossenkoppele","year":"2021","unstructured":"Ossenkoppele R, et al. Tau PET correlates with different Alzheimer\u2019s disease-related features compared to CSF and plasma p-tau biomarkers. EMBO Mol Med. 2021;13(8): e14398.","journal-title":"EMBO Mol Med"},{"issue":"1","key":"7199_CR43","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s13195-023-01302-w","volume":"15","author":"NS Mundada","year":"2023","unstructured":"Mundada NS, et al. Head-to-head comparison between plasma p-tau217 and flortaucipir-PET in amyloid-positive patients with cognitive impairment. Alzheimer\u2019s Res Ther. 2023;15(1):157.","journal-title":"Alzheimer\u2019s Res Ther"},{"issue":"6","key":"7199_CR44","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s12149-019-01344-x","volume":"33","author":"T Tago","year":"2019","unstructured":"Tago T, et al. Characterization of the binding of tau imaging ligands to melanin-containing cells: putative off-target-binding site. Ann Nucl Med. 2019;33(6):375\u201382.","journal-title":"Ann Nucl Med"},{"issue":"3","key":"7199_CR45","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/1523-1747.ep12260111","volume":"82","author":"MH Goldgeier","year":"1984","unstructured":"Goldgeier MH, et al. The distribution of melanocytes in the leptomeninges of the human brain. J Invest Dermatol. 1984;82(3):235\u20138.","journal-title":"J Invest Dermatol"},{"issue":"Supplement 1","key":"7199_CR46","doi-asserted-by":"publisher","first-page":"20S","DOI":"10.2967\/jnumed.121.263196","volume":"63","author":"C Groot","year":"2022","unstructured":"Groot C, et al. Tau PET imaging in neurodegenerative disorders. J Nucl Med. 2022;63(Supplement 1):20S\u201326S.","journal-title":"J Nucl Med"},{"issue":"3","key":"7199_CR47","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/ana.24850","volume":"81","author":"D Wilson","year":"2017","unstructured":"Wilson D, et al. Infratentorial superficial siderosis: classification, diagnostic criteria, and rational investigation pathway. Ann Neurol. 2017;81(3):333\u201343.","journal-title":"Ann Neurol"},{"key":"7199_CR48","doi-asserted-by":"crossref","unstructured":"Nordlund JJ, Boissy RE, Hearing VJ, King RA, Oetting WS, Ortonne J-P. The pigmentary system: physiology and pathophysiology. 2nd ed. Malden: Blackwell Pub; 2006.","DOI":"10.1002\/9780470987100"},{"key":"7199_CR49","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.exer.2014.09.010","volume":"128","author":"N Wolkow","year":"2014","unstructured":"Wolkow N, et al. Iron upregulates melanogenesis in cultured retinal pigment epithelial cells. Exp Eye Res. 2014;128:92\u2013101.","journal-title":"Exp Eye Res"},{"issue":"1","key":"7199_CR50","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00723-021-01386-3","volume":"53","author":"T Sarna","year":"2022","unstructured":"Sarna T, Swartz HM, Zadlo A. Interaction of melanin with metal ions modulates their cytotoxic potential. Appl Magn Reson. 2022;53(1):105\u201321.","journal-title":"Appl Magn Reson"},{"issue":"1","key":"7199_CR51","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41582-019-0281-2","volume":"16","author":"SM Greenberg","year":"2020","unstructured":"Greenberg SM, et al. Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways. Nat Rev Neurol. 2020;16(1):30\u201342.","journal-title":"Nat Rev Neurol"},{"key":"7199_CR52","doi-asserted-by":"crossref","unstructured":"Koemans EA, et al. Sex differences in histopathological markers of cerebral amyloid angiopathy and related hemorrhage. Int J Stroke. 2024;19(8):947\u201356.","DOI":"10.1177\/17474930241255276"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07199-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07199-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07199-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T09:56:19Z","timestamp":1757152579000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07199-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":52,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["7199"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07199-x","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,18]]},"assertion":[{"value":"30 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee (LMU Munich, application number 17\u2013569) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants provided written informed consent prior to the PET scan.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images in all Figures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"AD reports: research support: Siemens Healthineers, Life Molecular Imaging, GE Healthcare, AVID Radiopharmaceuticals, Sofie, Eisai, Novartis\/AAA, Ariceum Therapeutics; Speaker Honorary\/Advisory Boards: Siemens Healthineers, Sanofi, GE Healthcare, Biogen, Novo Nordisk, Invicro, Novartis\/AAA, Bayer Vital, Lilly, Peer View Institute for Medical Education, International Atomic Energy Agency: Stock: Siemens Healthineers, Lantheus Holding, Structured therapeutics, Lilly; Patents: Patent for 18F-JK-PSMA- 7 (Patent No.: EP3765097A1; Date of patent: Jan. 20, 2021). MB received speaker honoraria from Roche, Iba, GE healthcare and Life Molecular Imaging, is an active advisor of MIAC, and advised GE Healthcare Life Molecular Imaging.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}